CLDN18 and cancer: Abnormal expression of Claudin-18 is frequently observed in the development and progression of various primary malignant tumors, including gastric cancer, pancreatic cancer, oesophageal cancer, ovarian cancer and non-small cell lung cancer (Liu et al., 2022a).